CI-1021
| CI-1021 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
CI-1021 is a chemical compound that has been investigated for its potential use in the treatment of various medical conditions. It is primarily known as a selective antagonist of the neurokinin-1 receptor (NK1 receptor), which is involved in the modulation of pain and inflammation, as well as the regulation of mood and anxiety.
Pharmacology[edit]
CI-1021 functions by blocking the action of substance P, a neuropeptide that binds to the NK1 receptor. Substance P is associated with the transmission of pain signals and the regulation of emotional responses. By inhibiting this interaction, CI-1021 may reduce pain and have anxiolytic effects.
Clinical Research[edit]
Research into CI-1021 has focused on its potential applications in treating conditions such as chronic pain, depression, and anxiety disorders. However, as of the latest updates, CI-1021 has not been approved for clinical use, and its development status remains uncertain.
Mechanism of Action[edit]
The NK1 receptor is a G-protein coupled receptor that, when activated by substance P, initiates a cascade of intracellular events leading to the sensation of pain and the modulation of mood. CI-1021, by acting as an antagonist, prevents these effects by blocking the receptor.
Potential Applications[edit]
- Pain Management: CI-1021 has been studied for its potential to alleviate chronic pain conditions by interfering with the pain signaling pathways.
- Psychiatric Disorders: Due to its effects on mood regulation, CI-1021 has been explored as a treatment for depression and anxiety.
Safety and Efficacy[edit]
The safety profile of CI-1021 has been evaluated in preclinical studies, but comprehensive clinical trials are necessary to establish its efficacy and safety in humans. Potential side effects and long-term impacts remain areas of active research.
Also see[edit]
| Receptor Antagonists | |
|---|---|
| Receptor Type | Example Antagonists |
| Adrenergic receptor | Propranolol, Prazosin |
| Cholinergic receptor | Atropine, Scopolamine |
| Dopamine receptor | Haloperidol, Clozapine |
| Histamine receptor | Ranitidine, Diphenhydramine |
| Serotonin receptor | Ondansetron, Risperidone |
| Glutamate receptor | Memantine, Ketamine |
| GABA receptor | Flumazenil, Bicuculline |
| Opioid receptor | Naloxone, Naltrexone |
| Angiotensin receptor | Losartan, Valsartan |
| Pharmacology | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
